Raymond Debbane - 19 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Director
Signature
/s/ Raymond Debbane
Issuer symbol
LXRX
Transactions as of
19 Feb 2026
Net transactions value
+$219,755
Form type
4
Filing time
23 Feb 2026, 07:49:43 UTC
Previous filing
18 Feb 2026
Next filing
25 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DEBBANE RAYMOND Director 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS /s/ Raymond Debbane 23 Feb 2026 0001053890

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Purchase $71,965 +50,000 +3% $1.44 1,704,186 19 Feb 2026 Direct F1
transaction LXRX Common Stock Purchase $147,790 +100,000 +5.9% $1.48 1,804,186 20 Feb 2026 Direct F2
holding LXRX Common Stock 1,538,462 19 Feb 2026 By Avicenna Life Sci Master Fund LP and related parties
holding LXRX Common Stock 7,362,368 19 Feb 2026 By Invus Public Equities, L.P. and related parties
holding LXRX Common Stock 5,451,204 19 Feb 2026 By Invus US Partners, LLC and related parties
holding LXRX Common Stock 35,402,689 19 Feb 2026 By Invus, L.P. and related parties
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
F2 Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.